NexImmune Statistics
Total Valuation
NexImmune has a market cap or net worth of $4.61 million. The enterprise value is $1.45 million.
| Market Cap | 4.61M |
| Enterprise Value | 1.45M |
Important Dates
The next estimated earnings date is Tuesday, May 28, 2024, after market close.
| Earnings Date | May 28, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
NexImmune has 1.37 million shares outstanding. The number of shares has increased by 9.05% in one year.
| Shares Outstanding | 1.37M |
| Shares Change (YoY) | +9.05% |
| Shares Change (QoQ) | +1.51% |
| Owned by Insiders (%) | 21.95% |
| Owned by Institutions (%) | 11.66% |
| Float | 1.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 1.31 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.06, with a Debt / Equity ratio of 0.02.
| Current Ratio | 1.06 |
| Quick Ratio | n/a |
| Debt / Equity | 0.02 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -247.20% and return on invested capital (ROIC) is -921.43%.
| Return on Equity (ROE) | -247.20% |
| Return on Assets (ROA) | -167.40% |
| Return on Capital (ROIC) | -921.43% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$5.39M |
| Employee Count | 6 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.52% in the last 52 weeks. The beta is 2.06, so NexImmune's price volatility has been higher than the market average.
| Beta (1Y) | 2.06 |
| 52-Week Price Change | -55.52% |
| 50-Day Moving Average | 4.31 |
| 200-Day Moving Average | 5.22 |
| Relative Strength Index (RSI) | 40.87 |
| Average Volume (30 Days) | 61,498 |
Short Selling Information
The latest short interest is 6,243, so 0.46% of the outstanding shares have been sold short.
| Short Interest | 6,243 |
| Short Previous Month | 8,118 |
| Short % of Shares Out | 0.46% |
| Short % of Float | 0.54% |
| Short Ratio (days to cover) | 0.18 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -32.97M |
| Pretax Income | -32.34M |
| Net Income | -32.34M |
| EBITDA | -30.78M |
| EBIT | -32.34M |
| Earnings Per Share (EPS) | -$30.82 |
Balance Sheet
The company has $3.22 million in cash and $68,809 in debt, giving a net cash position of $3.15 million or $2.30 per share.
| Cash & Cash Equivalents | 3.22M |
| Total Debt | 68,809 |
| Net Cash | 3.15M |
| Net Cash Per Share | $2.30 |
| Equity / Book Value | 3.51M |
| Book Value Per Share | 2.56 |
| Working Capital | 316,727 |
Cash Flow
In the last 12 months, operating cash flow was -$31.43 million and capital expenditures -$44,492, giving a free cash flow of -$31.47 million.
| Operating Cash Flow | -31.43M |
| Capital Expenditures | -44,492 |
| Free Cash Flow | -31.47M |
| FCF Per Share | -$29.99 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
NexImmune does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -9.05% |
| Shareholder Yield | -9.05% |
| Earnings Yield | -702.11% |
| FCF Yield | -683.24% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on October 19, 2023. It was a reverse split with a ratio of 1:25.
| Last Split Date | Oct 19, 2023 |
| Split Type | Reverse |
| Split Ratio | 1:25 |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |